Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 2, 2025Journal of Cellular PhysiologyOpen Access

Parathyroid Hormone (1–34) Signaling for Bone Health in Breast Cancer Survivorship and Metastasis

View Full Paper
Ask AI
Bookmark
Share

Authors

SOShin-Young OhHOHa Ram OhCSChen Shen

Discussion

Loading...

Member takes

Implication

Review shows therapeutic agents improve bone health in cancer survivors, highlighting PTH (1–34) signaling pathways.

Key Points

  • Bone health improves after intermittent PTH (1–34) therapy, reducing fracture risk in breast cancer survivors.
  • This review identifies a link between abnormal p21-activated kinase 4 signaling and Wnt/β-catenin pathways.
  • Assessing the effectiveness of PTH (1–34) may enhance strategies against bone loss in breast cancer survivors.
  • Understanding osteoblasts' role is essential in addressing fragility and pathologic fractures during survivorship.

Cite This Study

Oh et al. (2025) studied this question.

synapsesocial.com/papers/692e3da16c9b3ab28c187bfchttps://doi.org/10.1002/jcp.70115
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 20242024 · 140 citations
  2. 2Lrp4, a Novel Receptor for Dickkopf 1 and Sclerostin, Is Expressed by Osteoblasts and Regulates Bone Growth and Turnover In Vivo2009 · 213 citations
  3. 3Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis2024 · 17 citations
  4. 4PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer2019 · 32 citations
  5. 5Association of Bone Metastasis With Early-Stage Breast Cancer in Women With and Without Precancer Osteoporosis According to Osteoporosis Therapy Status2019 · 52 citations